First, this study is very biased and flawed. Secondly, have the tech companies considered all of the resistance that we’re all going to face with the provider and payer communities plus their lobbyists when we try to promote medical AI, nanobots, etc.
I have seen some resistance mounted by some providers, some pharma, etc. against CRISPR. And, I believe this type of resistance is only going to hurt patients as well as many cancer survivors with a genetic predisposition to cancer, and other genetic mutations.
A study of mobile health apps’ impact on health care costs represents a limited but crucial step for assessing digital medicine.
Comments are closed.